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Abstract  
Background 
It has been demonstrated that cognitive behavioural therapy (CBT) has a moderate 
effect on symptom reduction and on general well being of patients suffering from 
psychosis. However, questions regarding the specific efficacy of CBT, the treatment 
safety, the cost effectiveness, and the moderators and mediators of treatment effects 
are still a major issue. The major objective of this trial is to investigate whether CBT is 
specifically  efficacious in  reducing  positive  symptoms  when compared  with non 
specific  supportive  therapy  (ST)  which  does  not  implement  CBT techniques  but 
provides comparable therapeutic attention. 
Methods/Design 
The  POSITIVE  study  is  a  multicenter,  prospective,  single blind,  parallel  group, 
randomised  clinical  trial,  comparing  CBT  and  ST  with  respect  to  the  efficacy  in 
reducing positive symptoms in psychotic disorders. CBT as well as ST consist of 20 
sessions altogether, 165 participants receiving CBT and 165 participants receiving ST. 
Major  methodological  aspects  of  the  study  are  systematic  recruitment,  explicit 
inclusion  criteria,  reliability  checks  of  assessments  with  control  for  rater  shift, 
analysis by intention to treat, data management using remote data entry, measures of 
quality  assurance  (e.g.  on site  monitoring  with  source  data  verification,  regular 
query  process),  advanced  statistical  analysis,  manualized  treatment,  checks  of 
adherence and competence of therapists. 
Research relating the psychotherapy process with outcome, neurobiological research 
addressing  basic  questions  of  delusion  formation  using  fMRI  and 
neuropsychological assessment and treatment research investigating adaptations of   - 3 - 
CBT for adolescents is combined in this network. Problems of transfer into routine 
clinical care will be identified and addressed by a project focusing on cost efficiency.  
Discussion 
This clinical trial is part of efforts to intensify psychotherapy research in the field of 
psychosis  in  Germany,  to  contribute  to  the  international  discussion  on 
psychotherapy  in  psychotic  disorders,  and  to  help  implement  psychotherapy  in 
routine  care.  Furthermore,  the  study  will  allow  drawing  conclusions  about  the 
mediators of treatment effects of CBT of psychotic disorders. 
Trial Registration 
Current Controlled Trials ISRCTN29242879 
   - 4 - 
Background  
Positive symptoms and cognitive behavioural therapy 
In the last two decades cognitive behavioural therapy (CBT) approaches for patients 
with schizophrenia have been developed which are specifically designed to reduce 
severity of positive symptoms. Positive symptoms such as persecutory delusions and 
hallucinations,  which  interfere  with  the  patient’s  ability  to  maintain  social 
relationships,  cause  serious  distress  and  life  disruption  in  patients  as  well  as  in 
relatives.  They  represent  hallmark  symptoms  of  psychosis  in  the  schizophrenia 
spectrum  disorders.  Even  with  advances  in  pharmacological  treatments  for 
schizophrenia and other psychotic disorders there is a large subgroup of patients 
characterised  by  nonresponse  to  antipsychotic  treatment.  Leucht  et  al.  [1]  report 
nonresponse rates between 38% and 76% even when second generation antipsychotic 
agents are prescribed.  
Against this background the investigation of other treatment approaches which may 
have  the  potential  to  reduce  positive  symptoms  has  high  priority.  It  has  been 
demonstrated that cognitive behavioural treatment (CBT) has a moderate effect on 
symptom reduction and on general well being of patients suffering from psychosis. 
The most recent meta analyses [2,3] state that the effect size of CBT is .37 for the 
reduction of positive symptoms. Based on the earlier meta analysis of Pilling et al. [4] 
the British National Institute of Clinical Excellence recommended CBT for routine 
care.  In  the  meantime,  also  in  other  countries  like  Germany  [5],  CBT  is  a 
recommended treatment modality for symptom reduction.   - 5 - 
Open questions 
However, many important questions remain unanswered, even if the efficacy of CBT 
for symptom reduction is increasingly well established.  
1. CBT for psychosis has been specifically developed for the reduction of positive 
symptoms. However, in contrast to more recent meta analyses the Cochrane meta 
analysis of Jones et al. [6] did not find significant reduction of positive symptoms 
indicating that more large scale clinical trials are needed. Wykes et al. [2] showed a 
significant  heterogeneity  in  their  meta analysis  which  might  point  to  unknown 
moderator effects. In particular the evidence for the specific efficacy of CBT should 
be  improved.  When  compared  to  Supportive  Treatment,  CBT  could  not  as  yet 
demonstrate clear superiority.  
2.  Patients  with  psychotic  disorders  might  conceivably  experience  symptom 
exacerbation  or  suicidal  crises  as  a  consequence  of  psychotherapeutic  efforts. 
Negative  effects  should  actively  be  sought  in  order  to  demonstrate  safety  of  the 
treatment. Therefore, Jones et al. [6] recommended investigating adverse events in 
CBT trials. However, Tarrier et al. [7] investigated suicidality in CBT trials and did 
not find any indication for an increased rate of suicide attempts. More data about 
treatment safety would be helpful for implementation of CBT, as scepticism among 
clinicians is widespread.  
3. Wykes et al. [2] found that outcome in CBT trials is associated with methodological 
rigor. Thus, more clinical trials applying rigorous methodology are needed in order 
to investigate whether treatment effects are stable even in high quality studies. 
4.  Psychotic  disorders,  in  particular  schizophrenia,  are  causing  a  considerable 
economic burden, e.g. in terms of costs of care. As resources for health care a limited, 
the cost effectiveness of single health services increasingly gains importance. CBT for   - 6 - 
psychotic  symptoms  is  currently  not  available  for  a  majority  of  patients  due  to 
therapeutic scepticism and limited resources. Against this background the question 
of cost effectiveness should urgently be addressed. 
5. Psychological theories of delusions emphasize either altered attention (selectively 
attending  to  evidence  in  favour  of  the  delusions),  or  disturbances  in  making 
unbiased inferences [8]. There are findings that patients with persecutory delusions 
preferentially  attend  threat  related  stimuli  or  threat  to  the  subject’s  self  concept 
[9,10]. Theory of mind skills and attributional style together with social perception 
(i.e. social cue perception and facial affect recognition) are considered as the main 
sub processes of social cognition [11]. The evidence in support of these hypotheses is 
limited and should be increased.  
6. The identification of moderators and mediators of treatment effects is a major issue 
for  further  development  of  treatment  strategies.  However,  it  has  as  yet  not  been 
studied whether CBT, if successful, alter these biases towards normality [12], and 
whether  the  success  of  CBT  critically  depends  on  cognitive  and  social cognitive 
skills.  Treatment  effects  on  neurocognitive  plasticity  have  thus  far  only  been 
described for “cognitive remediation” therapy in one fMRI working memory study 
with 6 patients. After therapy, a differential activation in the lateral frontal lobe has 
been  demonstrated  [13].  Well  described  cognitive  limitations  or  deficits,  e.g.  of 
declarative  memory  and  attention  span,  arise  from  enduring  (trait)  and  transient 
(state)  neurobiological  alterations  in  schizophrenia  patients,  with  considerable 
variation  being  present  between  subjects.  Such  cognitive  limitations  underlie  the 
development of specific symptoms [e.g. delusions, 14], are correlated with the degree 
of insight [15], and are limiting the success of any therapy which, like CBT, is based 
on  verbal  learning  and  requires  sufficient  attention.  Process outcome  research  in 
psychotherapy represents an empirical strategy for determining, which aspects of the   - 7 - 
therapeutic process are particularly helpful or harmful to patients [16]. This research 
links the two domains of process and outcome studies. Orlinsky et al. [16] view the 
therapeutic  contract  (treatment  model,  e.g.  rational,  goal  setting,  format),  the 
therapeutic  operations  (therapist  interventions),  and  the  therapeutic  bond 
(therapist’s  and  patient’s  interpersonal  behaviour)  as  the  essential  factors  of  the 
treatment process. These factors were empirically found to be linked with therapy 
outcome  in  many  psychiatric  disorders.  However,  regarding  psychotherapy  in 
psychotic disorders, such findings are still missing up to now. With respect to CBT 
for positive symptoms in psychotic disorders process outcome research is not yet a 
major focus. Studies on this topic focus mainly on effectiveness [e.g. 17,18,19].  
Objectives 
The  major  objective  of  this  trial  is  to  investigate  whether  CBT  is  specifically 
efficacious  in  reducing  positive  symptoms  when  compared  with  non specific 
supportive treatment (ST) which does not implement CBT techniques but provides 
comparable therapeutic attention. 
The  trial  is  accompanied  by  research  addressing  (a)  process outcome relationship 
dedicated  to  illuminating  the  question  of  the  active  ingredients  in  CBT  and  (b) 
neurobiological factors of delusion formation using functional magnetic resonance 
imaging (fMRI) and neuropsychological assessment, as well as (c) treatment research 
investigating adaptations of CBT in adolescents. Finally (d) problems in relation to 
disseminating  and  establishing  findings  in  routine  care  will  be  identified  and 
addressed by a project on cost effectiveness.   - 8 - 
Methods/Design 
General design aspects 
This study is a multicenter, prospective, single blind, parallel group,  randomised 
clinical trial (principal investigator(PI): SK), comparing CBT and ST with respect to 
the efficacy in reducing positive symptoms in psychotic disorders at nine months 
after inclusion . The study includes patients with persistent positive symptoms in six 
study centers applying a systematic recruitment strategy. CBT as well as ST consist 
of  20  sessions  altogether,  165  participants  receiving  CBT  and  165  participants 
receiving  ST  (table  1).  The  duration  of  treatment  for  each  study  patient  will  be 
approximately 36 weeks (i.e., 9 months). The study will be conducted in accordance 
to  GCP  and  CONSORT.  The  study  has  received  approval  from  the  local  ethics 
committees and is carried out in accordance with the latest version of the Declaration 
of Helsinki.  
Process of recruitment and obtaining written informed consent 
The recruitment for this study will address the catchment area of the participating 
institutions  (Departments  of  Psychiatry  and  Psychotherapy  of  the  Universities  of 
Bonn (PI: MW), Düsseldorf (PI: WW), Essen (PI: BM and GS), Frankfurt (PI: GW and 
JH),  Köln  (PI:  AB),  and  Tübingen  (PI:  SK)  with  their  associated  inpatient  and 
outpatient facilities). It aims at implementing a systematic recruitment plan which 
will  be  documented  according  to  CONSORT.  For  every  screened  patient  the 
inclusion and exclusion criteria will be recorded. All patients who fulfil the inclusion 
criteria will be offered to participate in this study. Thus, the resulting sample should 
represent a geographic cohort. 
Under conditions of routine care the patient population addressed by this trial is 
treated  in  psychiatric  hospitals  in  case  of  acute  exacerbations,  and  psychiatric   - 9 - 
outpatient facilities. In addition, patients are cared for by a considerable number of 
social  psychiatric  institutions  for  supported  housing,  supported  work,  and  other 
social psychiatric services.  
For  the  duration  of  the  recruitment  phase  all  inpatients  of  the  participating 
institutions  with  psychotic  disorders  will  be  screened  for  their  eligibility  before 
discharge  from  hospital.  Information  about  the  study  will  be  provided  to  the 
respective patients whenever possible. At the same time a detailed assessment of 
eligibility will take place. In outpatient departments a complete screening will be 
conducted for intervals of three months in order to implement comparable strategies 
for  systematic  recruitment.  In  addition,  recruitment  can  also  take  place  in  other 
outpatient services and practices as well as in institutions for supported housing or 
supported employment. Again, systematic recruitment strategies will be applied.  
The  registration  procedure  will  be  conducted  for  all  patients  with  a  tentative 
diagnosis of a psychotic disorder (see fig. 1 3). Patients without “obvious” exclusion 
criteria (e.g. age, foreign language, living outside of the catchment area, substance 
dependency  as  primary  problem,  mental  retardation,  ongoing  outpatient 
psychotherapy) will be approached and offered to be informed about the study. 
In case of refusal, the patient will be asked whether he is willing to give reasons for 
refusal and to allow for symptom assessment (PANSS) at the time of refusal. For this 
purpose a separate patient information and consent form will be applied. Only after 
giving consent for this interview the reasons for refusal from the viewpoint of the 
patient  and  the  current  symptomatic  status  will  be  assessed  and  recorded.  If  the 
patient does not give his consent to be interviewed for his reasons of refusal, the staff 
member who has provided the information about the trial will give his opinion about 
the major reason.   - 10 - 
In a first appointment potentially eligible patients will be informed about the study 
using  the  written  patient  information.  In  in patients  study  information  can  be 
provided in the hospital. The written patient information will be handed out when 
the patient signifies interest in study participation. In each case, obtaining written 
consent will take place at the beginning of a second appointment prior to inclusion 
examination. This second appointment has to take place in an out patient setting in 
order  to  ensure  the  patient’s  willingness  to  start  outpatient  treatment.  If  patients 
have by law a care giver responsible to provide support for the patient regarding 
health related decisions, patients can only be included in the trial if both the patient 
and the care giver give their informed consent. The care giver will be asked to show 
the staff member responsible for inclusion his/her certificate of appointment. 
For every screened patient a paper based screening and randomisation form will be 
filled  in  and  faxed  to  the  Coordination  Centre  of  Clinical  Trials  (CenTrial).  The 
screening and randomisation form will include a list of questions to be answered 
during the registration procedure. In particular, the inclusion and exclusion criteria 
will be recorded. Patient screening and randomisation will only be accepted from 
authorized investigators. At the end of the screening and randomisation form the 
investigators  will  document  the  intended  status  of  the  patient  in  the  trial:  (1)  as 
patient  to  be  included  and  randomised,  or  (2)  as  patient  not  to  be  included  but 
screened (with or without participation in the refusal survey). 
Inclusion Criteria 
In order to be included into the study, patients have to meet diagnostic criteria of 
schizophrenia (DSM IV 295.1, 295.2, 295.3, 295.6, 295.9), schizophreniform disorder 
(DSM  IV,  295.4),  schizoaffective  disorder  (DSM IV  295.7),  or  delusional  disorder 
(DSM IV 297.1), confirmed by a structured clinical interview (SCID I). Essential for   - 11 - 
inclusion is moderate or severe symptom intensity, i.e., a score of 4 or more, on the 
PANSS items “Delusions” (P1) or “Hallucinations” (P3). Furthermore, the presence 
of positive symptoms for at least three months with or without compliance regarding 
antipsychotic medication is necessary. Other inclusion criteria are fluency regarding 
the  German  language,  age  between  18  and  59,  a  verbal  IQ  >  80  assessed  by  a 
multiple choice  vocabulary  test  (“Mehrfachwahl  Wortschatz  Intelligenz Test”, 
MWT B, [20]), and willingness to give informed consent. Criteria for exclusion are 
any kind of organic brain diseases (other than schizophrenia) according to standard 
patient  examination  procedures  and  diagnosis  of  substance  abuse  or  substance 
dependence according to DSM IV/SCID I as primary clinical problem. 
Randomization 
All patients who give consent for participation and who fulfil the inclusion criteria 
will  be  randomized.  Randomisation  will  be  requested  by  the  staff  member 
responsible for recruitment and clinical interviews from CenTrial.  
In  return,  CenTrial  will  send  an  answer  form  to  the  study  therapist  who  is  not 
involved in assessing outcome of the study. This form will include a randomisation 
number. In every centre closed envelopes with printed randomisation numbers on it 
are  available.  For  every  randomisation  number  the  corresponding  code  for  the 
therapy group of the randomisation list will be found in inside the envelopes. The 
therapist  will  open  the  envelope  and  will  find  the  treatment  condition  to  be 
conducted in this patient. The therapist then gives the information about treatment 
allocation to the patient. Staff responsible for recruitment and symptom ratings is not 
allowed to receive information about the group allocation. 
As  part  of  the  efforts  of  quality  assurance  the  correctness  of  the  randomisation 
procedure in each patient will be monitored at the regular on site visits.   - 12 - 
The  allocation  sequence  will  be  generated  by  the  Institute  for  Medical  Biometry 
(IMB) applying  a  permuted  block  design with  random  blocks  stratified  by  study 
centre and medication compliance (favourable vs. unfavourable). The blocks should 
provide comparable numbers of patients in both conditions at any time in the course 
of the study. The block size will be concealed until the primary endpoint will be 
analysed. Throughout the study, the randomisation will be conducted by CenTrial in 
order  to  keep  the  data  management  and  the  statistician  blind  against  the  study 
condition  as  long  as  the  data  bank  is  open.  The  randomisation  list  remains with 
CenTrial for the whole duration of the study. Thus, randomisation will be conducted 
without any influence of the principal investigators, raters or therapists. 
Blinding 
This study implements a single blind design by completely separating treatment and 
assessment.  
Therapists will not be involved in assessing the treatment outcome. Raters will not be 
allowed to hold treatment sessions. Patients will be informed about their treatment 
allocation  by  the  therapist  but  not  by  the  raters.  Only  therapists  will  receive 
information  about  group  allocation.  Discussions  about  study  patients  are  not 
allowed  between  raters  and  therapists.  These  principles  were  part  of  the  staff 
training. 
At the beginning of every visit, the raters will instruct the patient not to reveal their 
treatment condition and not to talk about details of their treatment. The raters will 
have  to  complete  a  “blindness  protocol”  after  each  visit.  Any  unintentional 
disclosure  of  the  treatment  condition will be  documented.  Further,  the  raters  are 
asked to guess the study condition of the patient after each assessment. Among all   - 13 - 
documented guesses the rate of correct guesses should not be significantly different 
from chance (i.e. 50%). 
In order to avoid any bias in data analyses data will be primarily analysed by the 
intention to treat  principle.  Further,  statistical  analyses  will  be  conducted  by  an 
independent statistician of the Institute for Medical Biometry (IMB). The statistician 
is not involved in randomisation. The group variable (treatment allocation) will not 
be included until all data checks are completed. Even in case of severe adverse events 
no  unblinding  of  raters  will  be  necessary.  In  these  cases  therapists  will  start  the 
appropriate  crisis  management  strategies.  If  the  rater  is  the  first  staff  member  to 
detect an adverse event he will give notice to the therapist who will implement all 
appropriate measures. 
Cognitive behavioural therapy 
CBT  for  the  treatment  of  positive  symptoms  in  psychotic  disorders  is  based  on 
general  CBT  principles.  Participants  are  regarded  as  active,  self  responsible 
individuals.  During all phases  of  the  treatment  patients  are  requested to  actively 
participate in the treatment and to take responsibility for decisions how to proceed 
together with the therapist. The therapeutic process rests on the cooperation between 
patient and therapist. Whenever necessary, the therapist modifies his intervention in 
order to help the patient to engage in the therapeutic process. 
Treatment  is  built  on  a  case  formulation:  Patients  and  therapist  will  engage  in 
developing a shared definition of the major problem of the patient. When providing 
information about psychosis therapists will use a normalising and non stigmatising 
style  of  explanations.  The  formulation  has  to  address  (explicitly  or  implicitly) 
persistent  positive  symptoms.  A  shared formulation  is  thought  to  be a  necessary 
prerequisite for a successful treatment. The specific problems to be addressed in CBT   - 14 - 
are delusions and hallucinations. The treatment is aimed at helping the patient cope 
with these symptoms. A major principle of CBT is to link behaviour, emotion and 
cognition in order to provide a detailed understanding of the patient’s problems. 
Psychotic symptoms are understood as result of dysfunctional ways of perceiving 
and  interpreting  social  situations.  CBT  aims  at  correcting  the  person's 
misperceptions,  irrational  beliefs  and  reasoning  biases  as  well  as  at  reducing  the 
distress  caused  by  symptoms  and  the  improvement  of  social  functioning. 
Participants engage in monitoring own thoughts, feelings and behaviours. They are 
encouraged to test alternative ways of coping with the target symptom. Strategies for 
the treatment of delusions and delusional processing of hallucinations are to review 
the  information  processing  (perception bias, jumping  to  conclusions,  attributional 
bias, theory of mind deficit), to engage in schema work in order to modify potentially 
delusion related self schemata, to plan activities for reality testing which will provide 
evidence for or against the delusional conviction, and to help patients reduce the 
disruption of life and daily activities caused by the delusions. Strategies to reduce 
hallucinations  are  to  improve  the  patients  coping  strategies  (e.g.  systematic 
distraction strategies), and to identify and change social or internal stimuli related 
with increased hallucinatory experiences. 
Major stages of CBT can be described as follows:  
•  Engagement (strategies to foster motivation for treatment participation) 
•  Assessment (regarding symptoms and social problems) 
•  Developing understanding of psychotic symptoms using a “normalising” 
style of  providing information ) 
•  Case formulation and treatment planning 
•  Specific techniques designed to address delusions and hallucinations   - 15 - 
•  Specific techniques designed to address dysfunctional beliefs and schemata 
•  Specific techniques designed to improve social functioning 
(See figure 4) 
The CBT manual of the POSITIVE study is published in German language at the 
research network’s homepage (www.psychose psychotherapieforschung.de) 
Supportive Therapy 
ST  will  be  used  as  comparator  in  order  to  control  for  non specific  elements  of 
therapeutic contact. Psychotherapy outcome is generally thought of as consisting of 
both  specific  and non specific  effects.  Non specific  effects like  emotional  support, 
therapeutic attention, empathic listening, implementation of therapeutic optimism 
and others are the result of every successful therapeutic relationship. In contrast, 
therapeutic outcome, which is directly linked to specific and well defined treatment 
strategies, is called specific effect. It is hypothesised that CBT produces specific and 
non specific factors whereas ST should only result in non specific factors. ST does 
not rely on specific theories or assumptions about the causes of positive symptoms in 
psychotic disorders. ST will focus on the patients’ experiences and daily activities. 
The sessions will focus on neutral topics, such as hobbies, sports, and current affairs. 
Therapists will engage in listening to the patient, in being empathic, in helping the 
patient structure the available time and discussing problems in way friends would 
do. Thus, ST is thought as an active treatment with respect to the patient therapist 
relationship and with respect to therapeutic commitment [21]. In the treatment of 
patients  suffering  from  psychotic  disorders  these  ingredients  are  viewed  to  be 
essential as it has been shown consistently that the social network of these patients is 
limited. To have at least one trustworthy person to talk to may be the most important 
ingredient  in  any  kind  of  treatment.  However,  with  respect  to  specific  processes   - 16 - 
related to modification of psychotic beliefs, ST is not an active treatment. Strategies 
specifically designed to change misperceptions or reasoning biases are not part of ST.  
Major aspects of ST will be: 
•  Engagement 
•  Assessment of social problems and interests of the patient 
•  Treatment planning 
•  Focus on housing, work, leisure time, hobbies, and events, as adequate. 
Psychotic or affective symptoms will not directly be tackled in any way. (See figure 
5) 
The ST manual of the POSITIVE study is also published at the research network’s 
homepage (www.psychose psychotherapieforschung.de). 
Formal characteristics of study therapies 
CBT and ST are individual outpatient treatments of 20 sessions over 9 months (7 
sessions in the first seven weeks, followed by 13 fortnightly sessions)  
CBT as well as ST will be conducted by specifically trained psychotherapists on the 
basis  of  a  treatment  manual.  Each  therapist  conducts  both  the  CBT  and  the  ST 
treatment. In order to take responsibility as study psychotherapist, staff members 
have  to  have  at  least  one  year  of  clinical  experience  as  clinical  psychologist  or 
resident  in  psychiatry.  In  addition,  they  have  to  be  enrolled  in  formal  training 
programs for cognitive behavioural therapy or have to have completed their formal 
training.  
In the case of interruptions of the study therapies due to rehospitalisation of patients, 
holidays, other illnesses of patients, illness of therapists etc. the treatment will be 
continued as soon as possible. However, continuation is only possible within a time   - 17 - 
frame of 9 months after study inclusion. Thus, within 9 months after study inclusion 
interruptions of participation will not result in termination of the study treatment, 
exclusion from the study or a new screening. When continuing the treatment the 
remaining sessions will be scheduled on a weekly basis as long as necessary. Thus, 
even patients with longer interruptions will have the chance of getting a maximum 
of the 20 sessions. In each case, study therapies have to be terminated 9 months after 
study inclusion (primary endpoint).  
Primary Endpoint 
The primary endpoint for the biometrical evaluation of the therapy is the Positive 
Score  of  the  Positive  and  Negative  Syndrome  Scale  (PANSS,  [22 24]).  This 
psychopathological rating scale represents a common standard rating used in a wide 
range  of  outcome  studies  in  schizophrenia.  It  will  be  assessed  9  months  after 
inclusion of the participant.  
The PANSS positive score is defined by seven items of the PANSS (P1 – P7), all 7 
point rated with higher scores representing increasing levels of psychopathology. It 
will be computed as the mean of these seven items in order to provide a score that is 
easy to interpret on the scale of a single item. 
The German version of the PANSS was evaluated for interrater reliability by Müller 
et al. [25] and was used for the assessment of the primary endpoint by most of the 
studies of the German Research Network on Schizophrenia [26].  
For the purpose of this trial PANSS is regarded as a validated assessment instrument 
for positive symptoms. No own validation studies on the PANSS will be conducted. 
Moreover, the normal distribution and other prerequisites for parametric analyses 
(e.g. interval scale type) of the PANSS positive syndrome score will be assumed.   - 18 - 
In  order  to  ensure  the  interrater  reliability  of  the  rater  responsible  for  patient 
assessments in this study, the raters will be trained for PANSS rating. At the end of 
the  training  the  interrater  reliability  between  the  raters  will  be  assessed  using 
videotaped interviews. Three videos will be assessed by all raters and the reliability 
will  be  statistically  evaluated  by  the  intraclass  correlation  coefficient  (ICC).  The 
reliability will be regarded as acceptable if the ICC of the PANSS positive score will 
be .8 or higher. If the ICC is lower than .8 the rater training will be continued until 
the criterion is fulfilled. Assessment for reliability will be repeated in case of any 
change of raters. 
During the course of the study the interrater reliability will be assessed regularly 
every  year  in  order  to  analyse  rater  shift.  It  will  be  reported  whether  raters 
demonstrate a tendency of higher or lower ratings at the end of the study.  
As persistent positive symptoms are chronic symptoms which change very slowly a 
two year follow up after completion of treatment will be conducted. The primary 
endpoint will be analysed also at the end of the follow up period.  
Endpoints of Safety 
Endpoints of safety are  
•  Death caused by suicide 
•  Suicide attempt 
•  Suicidal  crisis  (explicit  plan  for  serious  suicidal  activity  without  suicide 
attempt) as defined in Calgary Depression Rating Scale for Schizophrenia 
[CDSS; 27], item 8, rating 2) 
•  Severe symptomatic exacerbation, defined by the Clinical Global Impression 
Scale  (CGI)  which  includes  ratings  of  illness  severity,  changes  in  overall   - 19 - 
clinical status, and therapeutic effects. A rating of CGI2 ≥ 6 and CGI 1≥ 6 
would be regarded as severe adverse event. 
Information about these safety parameters is recorded in the CRF every four weeks 
by the study rater as part of the regular clinical assessment.  
Secondary Endpoints 
A complete overview over the endpoints of this trial is given in table 2. Secondary 
endpoints will cover additional aspects of outcome, such as the course of symptoms 
and insight into the disorder. Results regarding secondary outcomes will only be 
interpreted as exploratorily. In particular, PSYRATS [28] provides information about 
the distress caused by symptoms, AMDP [29] provides additional information about 
the content of delusions, and SUMD [30] allows for a more detailed analysis of the 
patient’s self awareness regarding symptoms, i.e. insight.  
Treatment effects in the field of psychiatric disorders should always be assessed also 
from the viewpoint of the patient. However, a disorder of self evaluation is part of 
the positive syndrome which is the reason for choosing observer ratings as primary 
endpoint. On the other hand, the general rating of patients about their symptoms is 
important and is represented by the following secondary endpoint. 
The Symptom Checklist [SCL 90 R;31] assesses subjectively felt impairments due to 
somatic  and  psychic  symptoms  within  a  frame  of  seven  days.  The  SCL 90 R  for 
example also assesses psychotic or depressive symptoms. Thus, self ratings of these 
symptom dimensions seem to be a sensible completion of symptom ratings. As CBT 
is supposed to reduce symptoms we hypothesize, that SCL scores will be lower in 
CBT compared to ST at T9.  
Low  self esteem  might  be  viewed  as  a  product  of  the  schizophrenic  patient’s 
experience  of  positive  as  well  as  negative  symptoms  and  its  deleterious  social   - 20 - 
consequences  [32].  On  this  background,  the  self  concepts  as  measured  by  the 
Frankfurt Self Concept Scales [FSKN, 33] will be assessed. The subscales of this self 
rating  questionnaire  assess  attitudes  towards  the  own  person  (e.g.  self  esteem). 
Cognitive  behavioural  therapy  might  have  a  beneficial  impact  on  self esteem  in 
schizophrenic patients [32]. Since self concepts do usually change slowly the FSKN 
will only be applied at baseline, post treatment, 6 month follow up, and 12 month 
follow up.  
Traditional  instruments  that  measure  self esteem  may  not  relate  directly  to  the 
schema  construct  as  outlined  in  recent  cognitive  models.  The  Brief  Core  Schema 
Scales [BCSS; 34] aim to provide a theoretically coherent self report assessment of 
schemata concerning self and others in psychosis. The scales assess four dimensions 
of  self  and  other  evaluation:  negative self,  positive self,  negative other,  positive 
other. The BCSS will be applied at the same assessment points as the FSKN. 
Quality control/Monitoring 
As an instrument for quality control and quality assurance the clinical trial will be 
monitored. Monitoring will be performed by the Coordination Centre for Clinical 
Trials  at  University  Hospital  Tuebingen  (CenTrial)  according  existing  standard 
operating procedures (SOPs). The purposes of the monitoring are to verify that the 
rights and well being of the subjects are protected, that the reported trial data are 
accurate, complete, and verifiable from source documents, and that the conduct of 
the trial is in compliance with the study protocol/amendments, with GCP, and with 
applicable regulatory requirements. The extent and nature of the monitoring will be 
determined in a monitoring manual before starting the trial. For every on site visit a 
monitoring report will be submitted to the sponsor. Status reports of the monitor will 
inform the sponsor regularly about the actual status in the trial sites.    - 21 - 
Data Management 
Case report forms must be completed according to the following schedule: 
a) Before the treatment starts: the patient must be screened/randomised at CenTrial. 
For that purpose all relevant data must be reported. 
b)  Documentation  of  the  treatment  and  follow up  visits:  Each  visit  should  be 
documented immediately. 
c) Upon occurrence of a Severe Adverse Event (SAE) 
All SAEs occurring during the observation period of 9 months must be reported by 
fax  to  the  sponsor’s  medical  expert,  the  medical  director  of  the  Department  of 
Psychiatry and Psychotherapy of the University of Tuebingen. All forms must be 
dated and signed by the responsible investigator or one of his/her authorized staff 
members. 
This study is designed to be documented mainly via internet. The study software 
koordobas,  an  Oracle based  application  of  the  IMB,  will  be  used  for  the  data 
management. This application was in full compliance with GCP requirements (e.g. 
audit  trail,  validation)  at  the  start  of  the  trial.  The  eCRF  data  are  reported  by 
authorized investigators via internet on the specific case report forms (eCRFs). The 
case report forms (eCRFs) must be completed, dated and signed electronically by the 
investigator or one of his/her authorized staff members as soon as the requested 
information is  available.  The  list  of  staff  members  authorized  to  sign  case  report 
forms  (with  a  sample  of  their  signature)  have  been  sent  to  CenTrial  by  the 
responsible investigators before the start of the study. 
In all cases, it remains the responsibility of the investigator to check that case report 
forms  are  completely  and  correctly  filled  in.  The  data  manager  will  perform 
extensive  consistency  checks  on  the  eCRFs  and  issue  Query  Forms  in  case  of   - 22 - 
inconsistent data. Those Query Forms must be immediately answered and signed by 
the investigator (or an authorized staff member). The original must be returned to 
CenTrial and a copy must be appended to the investigator's copy of the eCRFs. 
If an investigator (or an authorized staff member) needs to modify an eCRF after the 
original eCRF has been filled in and returned, he/she can change it by notifying the 
Data Centre electronically appending a print out of the notification to his own copy 
of the eCRFs. All modifications will be protocolled by the audit trail of the study 
software. 
All study related data (electronic as well as on paper) will be stored for 10 years in 
the  archive  of  the  Department  of  Psychiatry  and  Psychotherapy,  University  of 
Tuebingen.  
The audio tapes of therapy sessions will be stored in locked filing cabinets. They are 
to be labeled with the patients ID only. Access to the audio tapes is permitted only 
with  written  permission  of  the  principal  investigator.  The  audio  tapes  will  be 
destroyed after finishing the data analysis. 
Assessment,  storing,  processing,  and  deleting  of  person  related  data  will  be 
conducted in accordance to German law. 
Sample size calculation 
The primary endpoint analysis will be conducted with linear mixed models (LMM, 
[35]). As software for sample size calculation for the analysis of longitudinal data 
using multilevel mixed models is not available, we calculated the sample size for 
classical ANOVA using nQuery 4.0.  
The power calculation is based on published results about CBT for persistent positive 
symptoms. For the comparison between CBT and TAU Tarrier et al. [36] reported 
Effect Sizes (ES: (meanTAU meanCBT)/SDTAU) of 0.33 0.66 for the 18 month follow up.   - 23 - 
Tarrier et al. (1998) found an ES of 0.48, Kuipers et al. [37] an ES of 0.6, and Sensky et 
al. [19] an ES of 0.5. In a review Gould et al. [38] found a range of ES from 0.2 to 1.26. 
The reported variance differs to a great extent indicating considerable differences 
with regard to samples or treatments. A recent effect size analysis applied broader 
inclusion criteria for studies and resulted in an ES of .57 for acute patients (post 
treatment analysis) and an ES of 0.27 in chronic patients [3]. These reviews show 
considerable efficacy of CBT when compared to treatment as usual. However, this 
study  focuses  on  the  difference  between  CBT  and  Supportive  Treatment  (ST). 
Unfortunately, the power calculation is more difficult for this comparison as fewer 
studies are available. According to a review of Tarrier et al. [36] the following studies 
have included ST control groups: Tarrier et al. [18], Haddock et al. [28], Pinto et al. 
[39], Lewis et al. [40], and Durham et al. [41] . The effect sizes vary between  .49 in a 
study including only 21 patients [28] and .99 in a study with 37 patients [39]. In 
addition,  sample  characteristics  and  endpoints  are  different  between  the  studies. 
Thus,  it  does  not  seem  possible  to  make  assumptions  about  the  ES  for  the 
comparison between CBT and ST based on the literature.  
Regarding drop out rates there is also much heterogeneity with a range between 0% 
and 36% [36,38]. The majority of studies reports drop out rates of less than 20%. As 
measures of quality control will be applied and monetary incentives for participation 
in the follow up examinations will be offered we expect a drop out rate of about 20 
%. 
On this background we aim to identify an effect size of more than .35 as significant 
given an anticipated drop out rate of 20%. An ES of .35 would be obtained if the 
PANSS Scores (Positive Syndrome) at the post treatment assessment were 12 for CBT 
and 14.5 for ST with a standard deviation of 7.14. An ES of less than .35 would be of 
limited clinical relevance.    - 24 - 
This results in n=130 per group for a power of 80% and a two sided significance level 
of  5%  (sample  size  calculated  by  nQuery  4.0,  Panel  MGT0).  The  confirmatory 
statistical  analysis  will  be  based  on  the  intention to treat  principle.  Patients  with 
missing  PANSS scores  at  T9  (post treatment)  will  be  included  with  the  last 
observation  carried  forward  (LOCF).  In  case  of  missing  PANSS scores  at  T9  the 
treatment effect will presumably be underestimated by using LOCF. To compensate 
for this underestimation the sample size should be adapted for drop out. Thus, we 
plan to include 330 patients (165 per study condition).  
As assumptions about the real effect size cannot be based upon the literature we 
calculated different scenarios: in case of a lower effect size and/or drop out of more 
than 20% the statistical power will be reduced. For example, a reduced ES of 0.2 
would result in a power of only 36% for the drop out of 20%. An increased drop out 
of 30%would reduce the power to 74% for the minimum ES of .35. On the other 
hand,  a  more  favourable  ES  of  0.45  would  increase  the  power  to  85%  for  the 
maximum drop out rate of 20%. 
With a sample size of 330 individuals (165 each therapy group), ten assessments per 
patient,  one  primary  analysis  variable  (therapy)  and  one  covariable  (center),  the 
power should also be sufficient for a Mixed Model [42]. 
Table  3  gives  an  overview  over  the  number  of  patients  required  in  the  different 
stages of the trial and the required effort for treatment and assessment. In order to 
successfully include 330 patients 6 study centers have been included which were 
committed to participate actively in this trial.    - 25 - 
Statistical Analysis 
The primary endpoint for the biometrical evaluation (responsible statistician: CM) is 
the PANSS Positive Score of the Positive and Negative Syndrome Scale at the time of 
9 months after inclusion. It will be analysed after completion of T9 assessments.  
The statistical hypothesis for the confirmatory test of the primary endpoint is that the 
treatment groups are significantly different when analysed using multilevel linear 
mixed models with treatment and study centres as levels of analysis and adjustment 
for baseline values. The decision for maintaining or rejecting the null hypothesis will 
be made applying a two sided test with α=0.05. A two sided test will be chosen as 
the  published  results  about  the  comparison  of  CBT  and  ST  are  inconsistent.  The 
observed effects will be described by use of means including the appropriate (one 
sided) 95% confidence intervals.  
The confirmatory statistical evaluation of the efficacy of the CBT in this trial will be 
restricted to the primary endpoint. Only the rejection of the null hypothesis will be 
interpreted as statistical evidence for the efficacy of CBT. The confirmatory statistical 
analysis will be based on the intention to treat principle (ITT). In addition, a “per 
protocol” (PP) analysis will be conducted  
All secondary endpoints will be compared and statistically assessed for descriptive 
purposes and not in a confirmatory sense. The aim of the analysis is explorative data 
analysis, not hypothesis testing or generation of evidence for efficacy. Because of the 
explorative character of this part of the analysis, no a priori statistical analysis plan 
exists. If adequate, secondary endpoints will be compared and statistically assessed 
using covariance techniques with baseline values and centers as covariates. Changes 
of  scores  over  time  will  be  modeled  using  linear  or  non linear  or  nonparametric 
models as adequate. In addition, appropriate statistical methods of explorative data   - 26 - 
analysis  including  graphical  methods  and  descriptive  statistics  will  be  used.  No 
interim analysis and no subgroup analyses are planned. 
Medication 
Regarding  psychopharmacological  treatment  the  study  is  open  and  requires  no 
restriction of treatment. The sample size of this trials justifies the expectation of equal 
distribution of type (classical vs. atypical antipsychotics), dose, rate of non adherence 
to  medication,  prescription  of  other  psychopharmacological  treatment 
(antidepressants, mood stabilizers, benzodiazepines) in both treatment groups. 
However,  both  the  medication  dose and the medication  compliance are  potential 
confounders which have to be controlled for. In particular, it could be the case that 
medication  will  not  be  completely  independent  from  the  study  condition.  As 
medication has the potential to influence the course of symptoms it is important to 
observe  the  medication  carefully  to  allow  for  detailed  analysis  of  this  aspect. 
Medications and doses will be documented monthly. Side effects will be assessed at 
baseline as well as at the post treatment assessment T9. 
Medication compliance [43] will be rated monthly along a 7 point scale (with 1 = 
total  rejection  of  medication,  and  7  =  active  cooperation  and  full  acceptance  of 
medication). 
Assessment of adherence to treatment manuals 
To evaluate the adherence to the manuals a number of measures will be assessed. 
First, in order to systematically assess characteristics of form and content as well as 
aspects of adherence of treatment therapists filled in structured session reports after 
each treatment session. The session reports give information whether the treatment 
session was conducted as scheduled or cancelled by the patient and whether the 
session began on time or delayed. Further, the session reports show the duration of   - 27 - 
the  session,  the  primary  and  secondary  foci  of  intervention  (e.g.  establishing 
treatment  goals,  work  on  delusions),  the  use  of  manualized  treatment  material, 
reasons for non adherence to the agenda (e.g. due to symptomatic worsening, focus 
on current problems, non compliance of patient or other reasons), accomplishment of 
homework  by  the  patient,  and  the  cooperation  of  the  patient  as  rated  by  the 
therapist.  The  cooperation  rating  scale  is  a  fully  anchored  ordinal  scale  with  1 = 
excellent,  2 =  adequate,  3  =  sufficient,  and  4  =  poor.  The  session  reports  will  be 
available for all sessions conducted. An individual study therapy will be considered 
as having been conducted according to manual if a patient has attended at least 14 
treatment sessions. Further, two thirds of the sessions conducted have to fulfil the 
following  criteria:  duration  >40  and  <60  minutes,  use  of  manualized  treatment 
materials or strategies, and at least sufficient cooperation of the patient. 
Second, all treatment sessions (CBT and ST condition) will be audio taped if patients 
give their consent. A maximum of four audio tapes of each patient will randomly be 
selected for analyses: one of the first 3 sessions (early phase), one of the sessions 4 10 
(early middle phase), one of the sessions 11 17 (late middle phase), and one of the 
last 3 sessions (late phase). This procedure is independent of the actual number of 
treatment session a patient has participated in. The audio tapes will be checked with 
regard to manual adherence. Guided by a checklist it will be assessed whether or not 
the treatment session followed the CBT or the ST manual with regard to content, the 
material worked on, and the formal characteristics (e.g. duration of the session). The 
ST checklist also comprises items regarding an irregular application of CBT specific 
techniques.  Our  adherence  checklists  will  be  subjected  to  analysis  of  interrater 
reliability.  Since  mistrust  and  paranoia  are  core  symptoms  of  chronic  psychotic 
disorders,  we  expect  a  rate  considerably  below  100%  of  patients  who  give  their 
written informed consent for audio taping their therapy.    - 28 - 
Assessment of unspecific mechanisms of action 
According to Orlinsky’s and colleagues’ review [16] the strongest evidence linking 
process to outcome concerns the therapeutic alliance. Therapeutic alliance proved to 
be a common ingredient of all psychotherapeutic interventions [44] and to be at least 
modestly correlated with outcome [45,46]. The therapeutic alliance as well as other 
unspecific mechanisms of action (e.g. clarification, activation of resources, emotional 
involvement,  problem  solving)  will  be  assessed  using  the  Bernese  Post  Session 
Reports [47] for patients (BPSR P) and therapists (BPSR T). In the framework of the 
German Research Network on Schizophrenia we conducted factor analyses of both 
instruments in a sample of 111 first episode patients with schizophrenia participating 
in CBT for relapse prevention. We identified dimensions relating to the therapeutic 
alliance, therapy progress, emotional involvement, dissatisfaction with therapy, and 
others. Both instruments will be applied at the end of each therapy session of the 
CBT and the ST condition. The continuous application of the session reports will 
allow  examining  the  course  of  the  above  mentioned  unspecific  therapeutic 
mechanisms  during  the  CBT  and  ST.  We  expect  no  differential  course  of  these 
unspecific factors between the two treatment conditions.  
Assessment of therapist’s competence 
Establishing empirical collaboration between the patient and the therapist as a means 
for cognitive restructuring is a major aspect of the therapists’ competence in CBT. To 
measure the extent of empirical collaboration the four randomly selected audio tapes 
will be analysed by means of the Cognitive Therapy Scale for Psychosis [CTS Psy; 
48]. The CTS Psy consists of two subscales each with five items. The items are rated 
on  the  original  nominal  scale  (1  =  appropriately  included,  0  =  inappropriately 
omitted, and 9 = appropriately omitted) as wells as on a 5 point interval scale where   - 29 - 
higher scores indicate better competency. We designed this 5 point Likert scale to 
prevent potential ceiling effects. Scale I “general skills” includes the items agenda 
setting, feedback, understanding, interpersonal effectiveness, and collaboration; scale 
II  “specific  skills”  covers  guided  discovery,  focus  on  key  cognitions,  choice  of 
intervention,  homework,  and  quality  of  intervention.  The  specific  skills  will  be 
measured only in the CBT condition. The CTS Psy demonstrates excellent inter rater 
reliability,  good  validity,  and  sensitivity  to  changes  [48].  Furthermore,  we  will 
conduct own analyses on the interrater reliablity of our German adaptation of the 
CTS Psy. 
Regarding the application of general skills we expect no difference between the CBT 
and the ST condition. Further, according to the rationale of CBT, we hypothesize that 
the  quality  of  a  therapist’s  specific  skills  correlates  with  therapeutic  outcome 
(symptom reduction) in the CBT condition.  
The research addressing treatment adherence, the unspecific mechanisms of action, 
as well as the therapist’s competence are integrated within the sub project “Process 
and outcome in CBT for positive symptoms in psychotic disorders” (PI: AW). 
Assessment of safety of interventions during the treatment phase 
Safety of psychological intervention in schizophrenia has been assessed in terms of 
suicide rates and rates of serious symptom deteriorations. The Cochrane Reviews on 
Family Intervention [49], on Cognitive Behavioural Treatment of Positive Symptoms 
[50], on Cognitive Remediation [51], and on Psychoeducation [52] could demonstrate 
that neither the suicide rate nor the rate of relapse was increased in psychological 
intervention. The same result was reported by Tarrier et al [7] who conducted the 
most subtle analysis yet on this topic and included also an ST condition in their 
study. Thus, there is no indication in the literature for an increased risk for patients   - 30 - 
as a consequence of their participation in the treatment described in this protocol. 
However, based on clinical experience it seems important to consider the following 
major risks:  
(a) Increase of positive symptoms as a consequence of therapeutic overstimulation: It 
is known that positive symptoms may increase if the psychosocial stress is greater 
than  the  coping  ability  of  a  patient.  Thus,  a  forced  therapeutic  approach  may 
represent stress for a patient increasing the risk for symptom exacerbation.  
(b)  Suicide,  suicide  attempt  or  suicidal  crisis  could  occur  as  a  consequence  of 
dysfunctional coping with the negative psychological and social consequences of the 
disorder. 
However, this study provides optimal conditions to prevent major risks, to detect 
symptom  exacerbations  early,  and  to  intervene  early  and  sufficiently.  (a)  The 
symptoms are assessed frequently in short intervals by the rater as well as by the 
study therapist. (b) Therapists are trained to react to symptom deterioration. They 
will adapt their strategy to the patients’ needs. This is completely compatible with 
the  treatment  manual.  (c)  The  therapist  will  discuss  the  treatment  strategy  with 
clinically experienced supervisors. (d) A psychiatrist responsible for routine care is 
involved in  the  treatment.  Independent  of  the study  this  psychiatrist will  initiate 
crisis intervention whenever required. 
As  described  above  there  is  no  indication  for  specific  risks  or  enhanced  rates  of 
adverse  events  as  a  consequence  of  participation  in  CBT  or  ST.  However,  as  the 
safety of interventions for positive symptoms in schizophrenia have not been studied 
extensively this study will control for severe symptom exacerbations and suicidal 
crises as adverse events.  
Severe adverse events to be observed at every assessment throughout the trial are:  
•  Death caused by suicide   - 31 - 
•  Suicide attempt 
•  Suicidal  crisis  (explicit  plan  for  serious  suicidal  activity  without  suicide 
attempt) as defined in Calgary Depression Rating Scale for Schizophrenia 
[CDSS; 27], item 8, rating 2) 
•  Severe symptomatic exacerbation, defined by the Clinical Global Impression 
Scale  (CGI)  which  includes  ratings  of  illness  severity,  changes  in  overall 
clinical status, and therapeutic effects. A rating of CGI2 ≥ 6 and CGI 1≥ 6 
would be regarded as severe adverse event. 
The  safety  parameters  are  part  of  the  regular  clinical  follow up  examination 
conducted  by  the  study  rater  every  four  weeks.  In  addition,  study  participants 
remain  in  their  usual  routine  outpatient  treatment  and  will  therefore  see  their 
independent  psychiatrist  regularly.  The  routine  care  psychiatrist  and  the  study 
therapist are requested to exchange information about the status of the patient and to 
provide  an  optimal  individual  treatment.  The  study  rater  will  communicate  any 
information  about  adverse  events  to  the  routine  care  psychiatrist  and  the  study 
therapist. Thus, the study provides an optimal framework to immediately detect any 
complication in the treatment.  
Information about the safety parameters is recorded in the CRF every four weeks by 
the study rater. In addition, therapists are requested to assess the safety parameters 
in every session and to record their assessment in the session protocol.  
The observation of these events should result in a statistical remarkable result, if the 
incidence of events in one of the two groups will be higher than in the other group. 
The statistical observation will be done for a significance level of α=0.2 (two sided) 
and a power of 0.8 with the help of the software PEST (distributed by Whitehead).    - 32 - 
Analyses will be conducted three times: after 100, 200 and 300 patients reaching T3. 
When analysing the safety data, the full observation period of all patients and all 
available  data  will  be  considered.  The  safety  analyses  will  be  conducted  by  a 
statistician (CE) not involved in the design and analysis of this trial, using coded 
group labels A and B blinded for the real therapy groups.  
The results will be reported directly to the members of the independent advisory 
board. In case of rejection of the null hypothesis of equal incidence rates in the two 
groups, the advisory board will decide whether or not the study has to be stopped. 
We do not expect any difference regarding illness related events between the groups. 
Time schedule of the study and duration of subject participation  
Table 4 gives an overview over major phases of this trial. A long preparation phase 
was  necessary  due  to  the  multicenter  design  and  the  requirements  of  a  publicly 
funded  clinical  trial.  The  recruitment  phase  was  completed  in  January  2010.  The 
recruitment  phase  had  to  be  extended  as  the  availability  of  patients  who  where 
willing to give consent was limited in some study centers. However, the designed 
sample  size  could  be  included  and  the  post treatment  assessments  (T9)  will  be 
finalized in October 2010. Analyses of major outcome will begin in November 2010. 
Long term follow up data will be collected until October 2012. 
A single patient participates for a duration of 33 months consisting of the treatment 
phase (9 month) and the follow up phase (24 months). The time of “first patient in” 
until “last patient out” will be 67 months.  
Funding, role of funders, and “sponsor” responsibilities 
This  study  is  publicly  funded  by the  German Federal  Ministry  of  Education  and 
Research (Bundesministerium für Bildung und Forschung, BMBF), project number 
01GV0618. The study is part of the BMBF research program “Research Networks on   - 33 - 
Psychotherapy”. The funding agency selected projects on the basis of the vote of an 
international  review  board.  It  does  not  exert  any  influence  during  the  trial.  The 
responsibilities of the “Sponsor” in terms of the guidelines of good clinical practice in 
clinical  trials  (ICH GCP,  E6)  has  been  taken  by  the  University  Hospital  of  the 
University of Tübingen which delegated responsibility to the head of department of 
Psychiatry and Psychotherapy. 
Associated research 
Cognitive deficits and biases 
For  the  assessment  of  neurocognitive  deficits,  a  short  and  reliable 
neuropsychological  battery  consisting  of  tests  measuring  verbal  intelligence, 
attention, executive functions, and memory is administered. This battery has been 
widely employed in the BMBF funded German Research Network on Schizophrenia 
[53]  and  a  substantial  database  on  the  relationship  of  cognitive  deficits  with 
psychopathological symptoms, course of illness, and response to therapy has been 
gathered [54]. The assessment of cognitive biases or cognitive styles is an emerging 
field  of  research,  and  several  experimental  studies  have  found  evidence  of 
specifically  altered  performance in  delusional subjects [55,56].  Therefore,  the  sub 
processes of social cognition which might serve as mediating mechanisms will be 
assessed  in  detail  in  the  sub project  “Cognitive  deficits  and  cognitive  biases 
underlying  delusional  symptoms  and  therapeutic  change”  (PI:  MW).  Attribution 
style  is  assessed  with  the  Internal,  Personal  and  Situational  Attribution 
Questionnaire [IPSAQ; 57]. Usually, the attributional style of paranoid patients is 
altered  in  that  they,  similar  to  depressed  patients,  make  global  and  stable 
explanations for negative events, but, unlike depressives, they preferentially assume 
external causes, and particularly other people to be responsible [8]. Another aspect of   - 34 - 
disturbed  inferential  thinking  relates  to  the  evaluation  of  hypotheses.  In  tasks 
requiring one to make a good guess based on prior evidence, paranoid patients jump 
to conclusions prematurely, as if they need less evidence to be sure (this style has 
been termed epistemological impulsivity). One method to assess such a reasoning 
style is the Beads in a Jar Task of Garety and colleagues [58]; an adapted computer 
version of this task [59] is employed here. Finally, standardized pictures from the 
Pictures of Facial Affect set [PFA; 60] are applied to assess accuracy and speed of 
facial affect recognition. 
Neural correlates of cognitive biases 
A functional magnetic resonance imaging (fMRI) study (PI: TK) investigates major 
mediating factors of Blackwood’s model. Using fMRI differential effects of CBT and 
ST  on  cerebral  activation  is  being  investigated.  The  present  study  investigates 
neurophysiological  processes  underlying  the  development  and  amelioration  of 
symptoms  of  delusion.  The  neural  correlates  of  jumping  to  conclusions  and 
attributional  bias  will  be  investigated.  The  paradigms  of  the  fMRI  study  will  be 
complementary  to  those  applied  in  a  larger  sample  via  neuropsychological 
experiments  outside  the  scanner.  Extensive  reliability  and  quality  control 
measurements  ensure  the  validity  of  data  across  different  centres.  The  following 
questions will be addressed: What are the neural correlates of delusions taped by the 
dysfunctional processes of attributional bias and jumping to conclusions? Can future 
therapeutic  success  be predicted  on  the  basis of  specific  brain activation  patterns 
already before treatment? Which components of neural circuits can potentially by 
altered by CBT? Are there distinct brain structures that can be linked to delusions?   - 35 - 
Cost effectiveness 
An associated project assesses the cost effectiveness of the treatment (PI: HHK). The 
direct and indirect costs of both study arms are calculated prior, during and after 
therapy  using  a  modified  version  of  the  „Client  Sociodemographic  and  Service 
Receipt  Inventory“  [61].  The  CSSRI  assesses  the  overall  resource  utilization  of 
patients as well as productivity losses. To estimate costs these quantities are then 
valued  with  market  prices.  When  market  prices  are  not  available  administrative 
prices or mean costs are used to estimate so called “shadow prices”. 
To assess the health effects of CBT and ST, two different measures are used. On the 
one hand the EQ 5D [62], a generic measure of subjective health related quality of life 
comprising a health profile and a visual analogue scale is used prior, during and 
after therapy. From the EQ 5D, health state utilities are derived to calculate quality 
adjusted life years (QALYs) [63]. On the other hand an objective measure of positive 
symptoms (PANSS Score) is used to quantify treatment response.  
A  Markov  model  is built  to  estimate  the  ICER  using  long  term costs and  effects 
beyond the time frame of the study. Markov models simulate the course of a disease 
over time and thus allows for calculating long term costs and effects.  
Adaptation of CBT for adolescents  
This sub project (principal investigator: AB) represents a pilot study which focuses 
on the evaluation of extensions of CBT for adolescents with early onset psychosis 
(EOP). Objectives are to develop a modified CBT (mCBT) for adolescents with EOP, 
to explore its acceptance and feasibility and to provide data for a realistic estimation 
of  achievable  effect  size.  The  study  is  a  multicenter,  prospective,  parallel  group, 
randomised controlled trial. Forty two patients will be recruited. All participants will 
receive individual optimised psychiatric treatment as usual (TAU). mCBT will be   - 36 - 
provided for 50 % of the patients (n =21) in addition to TAU.  mCBT is an outpatient 
treatment  which  consists  of  20  individual  sessions  in  nine  months  and  five 
psychoeducation sessions with parents. All sessions will be conducted by specifically 
trained psychotherapists on the basis of a treatment manual.  
The  primary  endpoint  will  be  the  positive  syndrome  of  the  PANSS  at  T9  (post 
treatment assessment). Monthly assessments during the treatment phase will closely 
monitor  the  course  of  symptoms.  Patients  have  to  fulfil  DSM IV  criteria  of 
schizophrenia,  schizoaffective  disorder,  or  delusional  disorder,  confirmed  by  a 
structured clinical interview (SCID I). Decisive for inclusion is a score of 4 or more on 
the  PANSS items  “Delusions”  (P1)  or  “Hallucinations”  (P3)  or  „Unusual  thought 
content“ (G9) representing a moderate or severe symptom intensity. Furthermore the 
presence of positive symptoms for at least four weeks or more is necessary.  
Discussion 
Relevance of the POSITIVE study 
This clinical trial is part of efforts to intensify psychotherapy research in the field of 
psychosis  in  Germany,  to  contribute  to  the  international  discussion  on 
psychotherapy  in  psychotic  disorders,  and  to  help  implement  psychotherapy  in 
routine  care.  Furthermore,  the  study  will  allow  drawing  conclusions  about  the 
mediators of treatment effects of CBT of psychotic disorders. 
In an innovative approach the network combines clinical trials on the efficacy of CBT 
with research designed to analyse active ingredients of the treatment. The POSITIVE 
Study will presumably be the largest full scale clinical trial comparing CBT with ST. 
This comparison will allow drawing conclusions about the specific efficacy of CBT 
for the treatment of persistent positive symptoms in psychotic disorders. The projects   - 37 - 
of the research network will give information about the processes of CBT, the effects 
of CBT on cognitive biases as well as the neural basis of theses biases. The latter have 
not yet been studied, in particular with respect to treatment outcome. Further, a full 
economic evaluation of CBT will be conducted. To this day, no such data on cost 
effectiveness are available yet.  
Strength of the POSITIVE study design 
There are several strengths of our study design. To summarize, within a multicenter 
design  a  systematic  recruitment  procedure  with  clear  inclusion  criteria  is 
implemented. Randomisation is applied independent of investigators and therapists. 
The study is single blind and the success of blinding will be assessed a posteriori.  
Reliability checks for the primary endpoint have been conducted prior to the first 
patient inclusion and thereafter once a year. Thus, we will be able to control for intra 
rater shift over time.  
Further, assessment and analysis of severe adverse events is a crucial component of 
the POSITIVE Study. Thus, our clinical trial will be the first which gives detailed 
information about the safety of CBT on persistent positive symptoms.  
As an instrument for quality control and quality assurance the clinical trial will be 
monitored by a Coordination Centre for Clinical Trials. Manualized treatments with 
predefined  adherence  checks,  regular  supervision,  and  process outcome  analyses 
assure the quality of the study therapies.  
Finally,  the  POSITIVE  study  provides  an  adequate  sample  size  for  the  expected 
moderate  treatment  effect,  has  a  predefined  primary  endpoint  and  multilevel 
secondary endpoints. The elaborated statistical analysis will be done by an external 
statistician.   - 38 - 
Lines of interpretation 
There are two main lines of interpretation of the results of POSITIVE study.  
First, according to our hypothesis, CBT might be superior to ST with regard to the 
reduction of positive symptoms. This result will be interpreted as an evidence for the 
specific  efficacy  of  CBT.  In  this  case  it  will  be  interesting,  whether  the  cognitive 
biases (e.g. jumping to conclusions, external attribution style) have been changed and 
normalized in the CBT only and whether these changes can also be observed on a 
neural level. A significant association of the change of the cognitive biases on the one 
hand  side  and  the  change  in  positive  symptoms  on  the  other  hand  side  would 
support the basic assumption of CBT approaches that the cognitive biases are factors 
which  actually  mediate  the  treatment  effect.  In  addition  such  a  result  would 
substantially support psychological models of delusion formation [12] as it would 
show that psychological processes are involved not only in the development but also 
in the reduction of positive symptoms. However, if changes in positive symptoms 
are  not  associated  with  changes  in  biases  questions  will  arise  regarding  the 
hypothesised mechanism of action in CBT. The health economical analysis will add 
an additional aspect of evaluation as it will focus on cost effectiveness and not on 
efficacy. 
Second, CBT and ST might show no significant difference regarding reduction of 
positive symptoms. In this case CBT has no specific effect on positive symptoms and 
symptom changes are independent of the investigated psychotherapeutic treatments. 
As this trial does not include a “treatment as usual” (TAU) condition in order to 
maximise the statistical power the question will remain open, whether CBT and ST 
had any effect on positive symptoms. Effects of the “natural” course and effects of 
medication can not be identified using the present design. Even, if CBT and ST lead   - 39 - 
to comparable changes in positive symptoms it will be important to analyses changes 
in  cognitive  biases  as  these  treatments  might  build  on  different  mechanisms  of 
action. 
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Tables 
 
Table 1: Study design 
 
 
 
 
 
Study condition  CBT 
Cognitive Behavioural 
Therapy 
(+ standard care) 
ST 
Supportive Treatment 
 
(+ standard care) 
Major inclusion criteria   Patients with psychotic disorders,  
PANSS Delusion or – Hallucination ≥ 4,  
symptoms persistent for at least 3 months 
N=330  
(to be included in  
six study centres)  
 
165 
 
165  
Study treatment sessions 
(treatment duration 9 
months)  
 
20  
 
20  
Primary Outcome  Positive Symptoms (PANSS)  
at  post treatment assessment (nine months after 
inclusion) 
post treatment follow up   24 month   - 48 - 
Table 2: Timing of assessments of endpoints for safety and efficacy 
  T0 
T1,
2 
T3 
T4,
5 
T6 
T7,
8 
T9  F1  F2  F3  F4 
  pre 
treatment phase  
(monthly 
assessments) 
po
st 
follow-up  
(every 6 months) 
Month  0  1,2  3  4,5  6  7,8  9  15  21  27  33 
Inclusion Assessment                       
Structured Clinical Interview for DSM IV  x                     
Anamnestic interview  x                     
Safety                       
Severe Adverse Event asessment1    x  x  x  x  x  x  x  x  x  x 
CDSS [27]  x  x  x  x  x  x  x  x  x  x  x 
Clincal Global Impression (CGI)    x  x  x  x  x  x  x  x  x  x 
Efficacy                       
PANSS [22]  x  x  x  x  x  x  x  x  x  x  x 
PSYRATS [28]  x  x  x  x  x  x  x  x  x  x  x 
GAF and Social Status  x  x  x  x  x  x  x  x  x  x  x 
Blindness Protocol  x  x  x  x  x  x  x  x  x  x  x 
CSSRI3 [61]  x    x    x    x  x  x  x  x 
EQ 5D [64]  x    x    x    x  x  x  x  x 
SUMD [30]  x            x    x    x 
AMDP psychosis items2 [29]  x            x    x    x 
Side effect rating scale [65]  x            x    x     
SCL 90 R [31]  x            x    x    x 
FSKN [33]  x            x    x    x 
Neuropsychological test battery  x            x         
1Suicide,  Suicide  attempts, 
2  items  33-58, 
3includes  assessment  of  medication  and  medication 
compliance; CDSS: Calgary Depression Scale for Schizophrenia; PANSS: Positive and Negative 
Syndrome  Scale;  PSYRATS:  Psychotic  Symptom  Rating  Scales;  GAF:  Global  Assessment  of 
Functioning; CSSRI: Client Sociodemographic and Service Receipt Inventory; EQ-5D: Euro Quality 
of Life – 5 Dimensions; SUMD: Scale to Assess Unawareness of Mental Disorder; SCL: Symptom 
Check List; FSKN: Frankfurter Selbstkonzeptskalen (Frankfurt Self-Concept Scales) 
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Table 3: number of patients required in the different stages of the trial 
  total  per center 
required number of eligible patients (with 75% refusal)  1304  217 
number of patients to be included (incl. 20% drop out)  330  55 
number of patients to be analysed (ITT, LOCF)  330  55 
number of patients to be analysed per protocol  260  44 
treatment sessions (CBT and ST)  5530  922  
number of visits   4620  770  
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Table 4: Study phases 
Phase  Time 
Grant application and preparation  March 2005 – March 2007 
Recruitment  April 2007 – January 2010 
Treatment completion and completion of 
post treatment assessment 
February 2010 – October 2010 
Follow-up until 24 months after treatment  November 2010 – October 2012 
Start of Analysis of primary outcomes  November 2010  
 
 
 
 Figure 1Figure 2Figure 3Engagement 
Assessment and shared formulation 
 
Treatment plan  
Work on  
Delusionsal 
beliefs 
Hallucinations 
 
Dysfunctional 
cognitive 
schemata  
Social integration 
 
Therapeutic 
relationship 
relaxed 
atmosphere 
humor 
empathy 
limited self- 
disclosure of the 
therapist 
affirmation 
respect regarding 
patients’ 
autonomy 
 
- focus on 
maintenance of 
beliefs and safety 
behaviour 
- focus on 
information 
processing and 
cognitive bias 
(Threat perception, 
Jumping to 
conclusions, 
Externalising, 
intention of others) 
- reducing stress (in 
order to reduce 
activating events) 
- reevaluation of the 
source of voices  
- reality testing 
regarding meta 
cognitions (e.g. 
omnipotence of 
voices )  
- improving coping 
strategies for 
persistent 
hallucinations 
Schemas are stable 
patterns of 
information 
processing, eg. 
schema of  
- defectiveness 
- mistrust 
- isolation 
Focus on factors 
which reduce social 
integration like 
generalised negative 
expectations and 
deficits of social 
competences 
Figure 4Engagement 
Assessment and shared formulation 
 
Treatment plan  
Topics  Strategies 
Therapeutic 
relationship 
relaxed 
atmosphere 
humor 
empathy 
limited self- 
disclosure of the 
therapist 
affirmation 
respect regarding 
patients’ 
autonomy 
 
- Work 
- School 
- Living situation 
- Hobbies 
- Friends 
- Family 
- Physical health 
- Financial situation 
- Grooming 
- Every-day duties 
- Neighborhood 
- Enhancement of self-esteem 
- Activation of external ressources 
- Counseling & intstruction 
- Implicit problem solving 
- Structuring 
Figure 5